Shandong Buchang Pharmaceuticals Co., Ltd. Stock price

Equities

603858

CNE100002FV6

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-02-22 pm EST 5-day change 1st Jan Change
17.19 CNY +0.94% Intraday chart for Shandong Buchang Pharmaceuticals Co., Ltd. +2.02% +1.06%
Sales 2021 15.76B 2.19B Sales 2022 14.95B 2.08B Capitalization 23.24B 3.23B
Net income 2021 1.29B 179M Net income 2022 -1.66B -230M EV / Sales 2021 1.6 x
Net Debt 2021 1.82B 253M Net Debt 2022 422M 58.63M EV / Sales 2022 1.58 x
P/E ratio 2021
18.1 x
P/E ratio 2022
-14 x
Employees 8,491
Yield 2021
1.71%
Yield 2022
4.57%
Free-Float 40.84%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 14, 2023. CI
Buchang Pharma’s Drugs Retain National Medical Insurance Coverage MT
Shandong Buchang Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 360 million worth of its shares. CI
Shandong Buchang Pharmaceuticals Co., Ltd. authorizes a Buyback Plan. CI
Buchang Pharma's Unit Gets Nod to Test Colorectal Cancer Drug MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Haikou Xinyingyang Investment Partnership Enterprise (Limited Partnership) and Xi Chong agreed to acquire 14% stake in Buchang Health Industry (Zhejiang ) Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd.,Hu Cunchao, Li Hui, and Hu Cunchao for CNY 0. CI
Buchang Pharma Unit Gets Nod to Trial Cancer Treatment MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Selling Expenses of Chinese Listed Pharma Companies About 1.5x Higher Than Net Profits in 2022 MT
Buchang Pharmaceuticals to Set Up Medical Device Subsidiary MT
Buchang Pharma Unit Gets Nod to Make Amendments to Diabetes Drug MT
Buchang Pharmaceuticals to Invest 223 Million Yuan Into Old Factory Upgrade MT
Buchang Pharma's Unit Passes Regulator's Good Manufacturing Practice Evaluation MT
Zhao Yunhua agreed to acquire a 90% stake in Buchang Taoyiyun Health Technology Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. for CNY 1. CI
More news
1 day+0.94%
1 week+2.02%
Current month+13.77%
1 month+10.90%
3 months-4.82%
6 months-5.13%
Current year+1.06%
More quotes
1 week
16.42
Extreme 16.42
17.22
1 month
14.15
Extreme 14.15
17.64
Current year
14.15
Extreme 14.15
17.64
1 year
14.15
Extreme 14.15
23.30
3 years
14.15
Extreme 14.15
28.38
5 years
14.15
Extreme 14.15
33.12
10 years
14.15
Extreme 14.15
91.96
More quotes
Managers TitleAgeSince
Director of Finance/CFO 60 12-03-10
President 56 12-03-10
Chief Tech/Sci/R&D Officer 64 17-03-25
Members of the board TitleAgeSince
Chairman 58 12-03-10
Director/Board Member 62 12-03-10
President 56 12-03-10
More insiders
Date Price Change Volume
24-02-23 17.19 +0.94% 8,415,756
24-02-22 17.03 +1.13% 7,168,878
24-02-21 16.84 +0.84% 9,367,336
24-02-20 16.7 +0.36% 6,247,105

End-of-day quote Shanghai S.E., February 22, 2024

More quotes
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Company's main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Shandong Buchang Pharmaceuticals Co., Ltd. - Shanghai S.E.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer